 Otonomy, Inc. OTIC, a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on the statistical analysis plan related to the ongoing Phase 3 clinical trial of OTIVIDEX in Ménières disease. In response to questions received from the U.S. Food and Drug Administration FDA regarding use of the Generalized Poisson model to analyze the daily vertigo count data reported by patients, Otonomy submitted a revised statistical analysis plan that uses a statistical test called the Negative Binomial model for the primary analysis of the ongoing trial. Otonomy selected the Negative Binomial model to address the FDAs questions because it believes it provides the best fit of the OTIVIDEX clinical data based on the Phase 2b trial for patients with vertigo enrollment criteria matching the Phase 3 clinical trials, the AVERTS-2 Phase 3 clinical trial, and the integrated dataset from both trials. 